scPharmaceuticals reported a net loss of $15.6 million for the third quarter of 2023, compared to
$10.2 million for the third quarter of 2022.
scPharmaceuticals ended the third quarter of 2023 with $90.2 million in cash, cash equivalents and
short-term investments, compared to $118.4 million as of December 31, 2022.
As of September 30, 2023, scPharmaceuticals’ total shares
outstanding was 35,859,045.
Conference call and webcast information
scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2023 results today, Wednesday,
November 8, at 4:30 p.m. ET. Participants should dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) with the conference code 10022564.
To
access the Call me™ feature, which avoids having to wait for an operator, click here.
A
link to the live webcast can be found here.
Following the live webcast, a replay of the event will be archived on scPharmaceuticals’ website
for one year.
FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use
FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with
New York Heart Association (NYHA) Class II and Class III chronic heart failure.
FUROSCIX is not indicated for use in emergency situations or in
patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of FUROSCIX.
IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated
in patients with anuria, patients with a history of hypersensitivity to furosemide or medical adhesives and in patients with hepatic cirrhosis or ascites.
Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral
electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in
elderly patients.
In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic
encephalopathy and coma. Treatment in such patients is best initiated in the hospital.
Furosemide can cause dehydration and azotemia. If increasing
azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.
Cases of tinnitus and reversible or
irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses,
hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.